Strengthen drug safety - reducing the risk for patients and doctors when used off-label

Summary

Timely updating of the list of off-label use as well as review and clarification of reimbursement by statutory health insurance companies by the Federal Joint Committee (G-BA), highlighting both the side effects and the scientifically validated benefits of the active ingredient in the instructions for use and specialist information of medications, limiting off-label use to a minimum through targeted research

Machine translation from German. The official text remains authoritative.

Timeline

1. 19 May 2021

   Motion

   Strengthen drug safety - reducing the risk for patients and doctors when used off-label

   Source: BT

2. 20 May 2021

   Ausschussüberweisung

   Strengthen drug safety - reducing the risk for patients and doctors when used off-label

   Source: BT

3. 18 June 2021

   Recommendation and report

   Strengthen drug safety - reducing the risk for patients and doctors when used off-label

   Source: BT

4. 23 June 2021

   Beratung

   Strengthen drug safety - reducing the risk for patients and doctors when used off-label

   Source: BT

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

2 official files

• 19/30804

  Drucksache · DE · 18 June 2021

  ViewDownloadOpen at official source

• 19/29772

  Drucksache · DE · 19 May 2021

  ViewDownloadOpen at official source

Sponsors

• Fraktion der AfD · Fraktion der AfD · initiative

Related records

No cross-record relationships stored yet.